TOBY Gains FDA Breakthrough Status for MCED Test
AUSTIN, TEXAS, USA, April 14, 2026 TOBY, Inc. has received FDA Breakthrough Device Designation for its urine-based Multi-Cancer Early...
Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody NSCLC Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
AUSTIN, TEXAS, USA, April 14, 2026 TOBY, Inc. has received FDA Breakthrough Device Designation for its urine-based Multi-Cancer Early...
IRVING, Texas, USA, March 31, 2026 Caris Life Sciences has announced final results from the Achieve 1 study, demonstrating...
